---
title: "萬華媒體發佈年度業績 股東應占虧損 2583.1 萬港元 同比擴大 22.94%"
description: "智通財經 APP 訊，萬華媒體發佈截至 2025 年 3 月 31 日止年度的全年業績，營業額 3231.4 萬港元，同比減少 18.2%;股東應占虧損 2583.1 萬港元，同比擴大 22.94%;每股基本虧損 6.4 港仙。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/242171560.md"
published_at: "2025-05-28T09:59:02.000Z"
---

# 萬華媒體發佈年度業績 股東應占虧損 2583.1 萬港元 同比擴大 22.94%

> 智通財經 APP 訊，萬華媒體發佈截至 2025 年 3 月 31 日止年度的全年業績，營業額 3231.4 萬港元，同比減少 18.2%;股東應占虧損 2583.1 萬港元，同比擴大 22.94%;每股基本虧損 6.4 港仙。

智通財經 APP 訊，萬華媒體 (00426) 發佈截至 2025 年 3 月 31 日止年度的全年業績，營業額 3231.4 萬港元，同比減少 18.2%;股東應占虧損 2583.1 萬港元，同比擴大 22.94%;每股基本虧損 6.4 港仙。

### Related Stocks

- [00426.HK - 萬華媒體](https://longbridge.com/zh-HK/quote/00426.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/zh-HK/news/276024005.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/zh-HK/news/275851575.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-HK/news/276035104.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-HK/news/276051793.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/zh-HK/news/276016059.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。